Fast Mdx Ltd

The NGX 124 is a compact, ultra-fast, sample-to-result molecular diagnostics platform that runs extracted nucleic acid (NA) or direct qPCR assays. It features a 4-channel thermal cycler with highly thermally conductive 96 well SBS format microtitre plates. An onboard automated heat sealer ensures consistent sealing. Plates shuttle between dual heater blocks in ~1 second, with fluorescence captured mid-transfer for real-time analysis. Each run processes 4–92 patient samples, plus 4 controls. Aspiration is via the Pathtube® a UN3373-compliant sample tube with a pierceable cap. Two versions exist: one for 1ml direct qPCR; the other for 200μl extracted NA. Reagent-mixing algorithms reduce dead volumes, cutting waste. Intuitive software allows operation by lab technicians, reducing reliance on BMSs and freeing them for more complex tasks. The unit occupies 0.7m², is mounted on wheels, and installs in under 15 minutes. Output includes CT values, raw data, and filtered/unfiltered curves. Fast MDx is also developing AI tools for early detection of infection hotspots. Each NGX 124 can scale to tests per day (across 3 shifts), supporting pandemic preparedness. An Open Platform Unlike closed systems from major manufacturers, the CE IVDR and UKCA-marked NGX 124 is open. Labs can run their own LDTs or CE IVDd assays, driving innovation, reducing costs, and widening access to automated qPCR globally. Commercial Models 1. Subscription – Free platform, servicing and consumables included; labs pay per test with a monthly minimum. Outright Purchase – Labs buy the platform and consumables, with optional service contract. Labs retain freedom to use existing assay suppliers. Launching in the UK and EU in September 2025. Our Mission Fast MDx is a registered Social Enterprise with the aim todemocratise molecular diagnostics. We welcome collaborations with academics, charities, and funders to develop early detection screening programs that can transform global healthcare.